Delving into the Latest Updates on 4SCAR-CD70 with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

Target

CD70

Action

inhibitors

Mechanism

CD70 inhibitors(CD70 antigen inhibitors), Gene transference, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

B-cell lymphoma refractoryCD19 Expressing MalignanciesChronic Lymphocytic Leukemia

Originator Organization

Shenzhen Geno-Immune Medical Institute

Active Organization-

Inactive Organization

Shenzhen Geno-Immune Medical Institute

License Organization-

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Start Date01 Jun 2020

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

[+1]

NCT03125577

/ Unknown statusPhase 1/2IIT

Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies

The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Start Date15 Jul 2017

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

100 Clinical Results associated with 4SCAR-CD70

Login to view more data

100 Translational Medicine associated with 4SCAR-CD70

Login to view more data

100 Patents (Medical) associated with 4SCAR-CD70

Login to view more data

100 Deals associated with 4SCAR-CD70

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-cell lymphoma refractory	Phase 2	China	Shenzhen Geno-Immune Medical Institute	01 Jun 2020
CD19 Expressing Malignancies	Phase 2	China	Shenzhen Geno-Immune Medical Institute	15 Jul 2017
Chronic Lymphocytic Leukemia	Phase 2	China	Shenzhen Geno-Immune Medical Institute	15 Jul 2017